trending Market Intelligence /marketintelligence/en/news-insights/trending/drhjngv8djuwtskmuf7ahw2 content esgSubNav
In This List

Matinas BioPharma appoints vice chairman

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Matinas BioPharma appoints vice chairman

Matinas BioPharma Holdings Inc. appointed Patrick LePore as vice chairman of the board.

LePore served as the CEO, chairman and president of Par Pharmaceuticals Inc. from 2006 to 2012.

Matinas Biopharma said in a Sept. 6 news release that Lepore oversaw the sale of Par Pharmaceuticals to Texas Pacific Group for $2 billion in November 2012 and was appointed as the chairman. He oversaw the new company's $8 billion sale to Endo International PLC in 2015.

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications.